This is an evolving field. While the thought had been all the drugs were likely equivalent in efficacy (with no head to head trials) this has changed in the past week. Roche had a press release in which they announced the Phase III IMvigor211 study that evaluated atezolizumab in people with locall...

The therapeutic landscape for metastatic and locally-advanced urothelial cancers of the bladder and urinary tract has undergone significant paradigm change in the last few years with the introduction of anti-PD1/PDL1 immune checkpoint inhibitors. To date, five agents are approved by FDA, including a...